United States Antimony Financials
United States Antimony (UAMY) reported $39.3M in revenue for fiscal year 2025, up 162.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded expansion is reshaping the company faster than earnings, with assets and working capital growing ahead of cash generation.
FY2024 briefly paired positive operating cash flow with a net loss, but FY2025 swung to operating cash flow of-$9.7M even as gross margin improved to25.2% . The missing cash is visible on the balance sheet: inventory and receivables rose by roughly$14.4M , so the larger business became working-capital hungry and relied on$109.5M of financing to support its buildout.
The balance-sheet posture is unusual for a company expanding this aggressively: total liabilities were just
The income statement shows scale without operating leverage: FY2025 gross profit reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of United States Antimony's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for United States Antimony, and counted as zero in the overall score.
United States Antimony scores 38.02, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($821.7M) relative to total liabilities ($13.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
United States Antimony passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
United States Antimony reported a net loss of $4.3M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
United States Antimony generated $39.3M in revenue in fiscal year 2025. This represents an increase of 162.8% from the prior year.
United States Antimony's EBITDA was -$7.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 458.8% from the prior year.
United States Antimony reported -$4.3M in net income in fiscal year 2025. This represents a decrease of 150.8% from the prior year.
United States Antimony earned -$0.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Cash & Balance Sheet
United States Antimony recorded an outflow of $37.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 2195.3% from the prior year.
United States Antimony held $30.5M in cash against $58K in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
United States Antimony's gross margin was 25.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.9 percentage points from the prior year.
United States Antimony's operating margin was -21.6% in fiscal year 2025, reflecting core business profitability. This is down 5.5 percentage points from the prior year.
United States Antimony's net profit margin was -11.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.5 percentage points from the prior year.
United States Antimony's ROE was -3.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.0 percentage points from the prior year.
Capital Allocation
United States Antimony spent $449K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
United States Antimony invested $27.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 6358.1% from the prior year.
Not reported for fiscal year 2025.
UAMY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4M | $39.3M+162.8% | $14.9M+71.8% | $8.7M-21.3% | $11.0M+42.6% | $7.7M+48.0% | $5.2M-36.7% | $8.3M-8.5% | $9.0M-11.7% | $10.2M-14.0% | $11.9M-9.3% | $13.1M+21.7% | $10.8M-2.3% | $11.0M-8.5% | $12.0M-8.2% | $13.1M |
| Cost of Revenue | $30.1M | $29.4M+156.2% | $11.5M-4.7% | $12.0M+33.0% | $9.0M+31.0% | $6.9M+37.4% | $5.0M-44.6% | $9.1M+0.6% | $9.0M-9.3% | $10.0M-12.3% | $11.4M-16.0% | $13.5M+21.7% | $11.1M+0.4% | $11.1M+0.5% | $11.0M-3.8% | $11.4M |
| Gross Profit | $6.4M | $9.9M+184.8% | $3.5M+203.7% | -$3.3M-267.6% | $2.0M+138.0% | $839K+307.7% | $206K+125.2% | -$816K-53000.3% | $2K-99.4% | $275K-48.7% | $537K+230.1% | -$412K-21.5% | -$339K-728.3% | -$41K-104.0% | $1.0M-38.2% | $1.7M |
| SG&A Expenses | $4.7M | $3.1M+52.2% | $2.1M+25.0% | $1.6M+149.5% | $658K-2.9% | $678K+11.6% | $607K-10.0% | $674K-15.2% | $796K+22.9% | $648K-5.0% | $681K-7.4% | $736K+18.1% | $624K-15.3% | $736K-9.1% | $810K+89.3% | $428K |
| Operating Income | -$23.3M | -$8.5M-253.8% | -$2.4M+66.2% | -$7.1M-2130.1% | $348K+152.7% | -$660K+80.0% | -$3.3M+12.0% | -$3.8M-786.2% | $547K+157.0% | -$960K-17.5% | -$817K-0.9% | -$809K+49.1% | -$1.6M-18.7% | -$1.3M-319.9% | -$319K-135.7% | $892K |
| Interest Expense | N/A | N/A | N/A | N/A | $15K+173.4% | $6K-69.2% | $18K-77.0% | $78K-21.6% | $100K-6.5% | $107K-33.5% | $161K | $0-100.0% | $1K-75.3% | $5K+68.3% | $3K | $0 |
| Income Tax | N/A | $0 | $0 | $0-100.0% | $16K | $0 | $0 | $0+100.0% | -$332K | $0-100.0% | $298K | $0 | $0-100.0% | $229K+37.3% | $167K+58.2% | $106K |
| Net Income | -$16.3M | -$4.3M-150.8% | -$1.7M+72.7% | -$6.3M-1581.0% | $429K+808.9% | -$60K+98.2% | -$3.3M+10.5% | -$3.7M-520.6% | $873K+177.0% | -$1.1M+13.4% | -$1.3M-56.1% | -$839K+47.4% | -$1.6M+2.8% | -$1.6M-193.8% | -$559K-187.7% | $637K |
| EPS (Diluted) | — | -$0.04-100.0% | -$0.02+66.7% | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.03-200.0% | -$0.01-200.0% | $0.01 |
Not reported in any period shown, so not listed: R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
UAMY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $153.9M+344.3% | $34.6M+23.3% | $28.1M-19.0% | $34.7M-0.9% | $35.0M+163.2% | $13.3M-2.9% | $13.7M-22.0% | $17.6M+2.5% | $17.1M-3.6% | $17.8M-2.7% | $18.3M+10.4% | $16.5M+11.1% | $14.9M+11.3% | $13.4M+46.3% | $9.1M |
| Current Assets | $54.7M+164.7% | $20.7M+46.9% | $14.1M-34.9% | $21.6M-8.3% | $23.6M+1203.5% | $1.8M+41.3% | $1.3M-32.8% | $1.9M+21.8% | $1.6M-7.7% | $1.7M-20.8% | $2.1M-7.3% | $2.3M+20.6% | $1.9M-38.4% | $3.1M+4.7% | $3.0M |
| Cash & Equivalents | $30.5M+67.8% | $18.2M+52.7% | $11.9M-37.6% | $19.1M-10.8% | $21.4M+2857.3% | $722K+318.1% | $173K+205.0% | $57K+102.4% | $28K+178.3% | $10K-92.5% | $134K+8.0% | $124K+508.0% | $20K-98.0% | $1.0M+18341.3% | $5K |
| Inventory | $12.5M+905.2% | $1.2M-10.1% | $1.4M+0.8% | $1.4M+30.3% | $1.1M+62.3% | $650K+3.8% | $626K-17.1% | $755K-17.4% | $915K+6.9% | $856K-21.8% | $1.1M-23.7% | $1.4M+38.5% | $1.0M-13.2% | $1.2M+11.8% | $1.1M |
| Accounts Receivable | $4.2M+283.1% | $1.1M+75.9% | $625K-20.3% | $784K-12.0% | $891K+273.5% | $239K-16.1% | $284K-35.1% | $438K+20.9% | $363K-34.3% | $552K+30.6% | $423K-7.0% | $455K-21.1% | $576K+26.3% | $456K-68.3% | $1.4M |
| Total Liabilities | $13.0M+114.7% | $6.0M+134.7% | $2.6M-9.1% | $2.8M+7.5% | $2.6M-56.9% | $6.1M+17.0% | $5.2M-14.8% | $6.1M-9.2% | $6.8M+5.2% | $6.4M+10.7% | $5.8M+63.4% | $3.5M-8.7% | $3.9M+91.6% | $2.0M-14.4% | $2.4M |
| Current Liabilities | $10.2M+154.0% | $4.0M+346.4% | $897K-59.6% | $2.2M+7.2% | $2.1M-53.8% | $4.5M+12.6% | $4.0M+13.0% | $3.5M-10.6% | $3.9M+16.3% | $3.4M+39.2% | $2.4M+7.7% | $2.3M-9.0% | $2.5M+52.8% | $1.6M-17.7% | $2.0M |
| Long-Term Debt | $58K-70.1% | $195K | $0-100.0% | $218K+1.3% | $215K+527.2% | $34K-55.3% | $77K-92.5% | $1.0M-17.1% | $1.2M-15.9% | $1.5M-14.3% | $1.7M+140.1% | $715K-28.6% | $1.0M+536.5% | $157K-0.5% | $158K |
| Total Equity | $141.0M+392.8% | $28.6M+12.1% | $25.5M-19.9% | $31.9M-1.5% | $32.4M+350.4% | $7.2M-15.1% | $8.5M-25.9% | $11.4M+10.1% | $10.4M-8.5% | $11.3M-9.0% | $12.5M-4.1% | $13.0M+18.1% | $11.0M-3.0% | $11.3M+67.6% | $6.8M |
| Retained Earnings | -$45.5M-10.5% | -$41.1M-4.4% | -$39.4M-19.2% | -$33.1M-1.1% | -$32.7M-0.2% | -$32.7M-11.2% | -$29.4M-14.3% | -$25.7M+3.3% | -$26.6M-4.5% | -$25.4M-5.4% | -$24.1M-3.6% | -$23.3M-7.4% | -$21.7M-8.2% | -$20.0M-2.9% | -$19.5M |
Not reported in any period shown, so not listed: Goodwill.
UAMY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.1M | -$9.7M-536.5% | $2.2M+146.7% | -$4.8M-1805.5% | -$249K+89.7% | -$2.4M-86.2% | -$1.3M-11398.6% | -$11K+98.3% | -$657K-191.6% | $717K+68.3% | $426K+18.8% | $358K+134.6% | -$1.0M-541.3% | $235K-55.4% | $526K+26.1% | $417K |
| Capital Expenditures | $43.2M | $27.8M+6358.1% | $431K-71.8% | $1.5M-11.5% | $1.7M+166.4% | $648K+166.6% | $243K-69.3% | $793K-11.8% | $899K+146.0% | $366K-38.7% | $596K-65.1% | $1.7M-6.4% | $1.8M-33.2% | $2.7M-16.4% | $3.3M+46.0% | $2.2M |
| Free Cash Flow | -$71.3M | -$37.5M-2195.3% | $1.8M+128.5% | -$6.3M-217.8% | -$2.0M+35.8% | -$3.1M-98.8% | -$1.5M-92.6% | -$804K+48.3% | -$1.6M-542.9% | $351K+306.6% | -$170K+87.4% | -$1.4M+52.8% | -$2.9M-14.6% | -$2.5M+8.9% | -$2.7M-50.6% | -$1.8M |
| Investing Cash Flow | -$81.1M | -$87.4M-207641.1% | -$42K+96.9% | -$1.3M+24.9% | -$1.8M-173.4% | -$653K-168.7% | -$243K+38.1% | -$393K-143.6% | $901K+346.5% | -$366K+37.3% | -$583K+65.8% | -$1.7M+6.7% | -$1.8M+33.2% | -$2.7M+22.2% | -$3.5M-56.9% | -$2.2M |
| Financing Cash Flow | $145.6M | $109.5M+2545.7% | $4.1M+486.3% | -$1.1M-300.1% | -$268K-101.1% | $23.8M+1033.4% | $2.1M+353.1% | $463K+308.9% | -$222K+33.5% | -$333K-1088.6% | $34K-97.5% | $1.4M-54.3% | $3.0M+95.3% | $1.5M-61.9% | $4.0M+188.9% | $1.4M |
| Dividends Paid | N/A | N/A | $0-100.0% | $788K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $449K | N/A | $0-100.0% | $203K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
UAMY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 25.1%+1.9pp | 23.2%+61.7pp | -38.5%-56.5pp | 18.1%+7.2pp | 10.8%+6.9pp | 3.9%+13.8pp | -9.9%-9.9pp | 0.0%-2.7pp | 2.7%-1.8pp | 4.5%+7.7pp | -3.1%0.0pp | -3.1%-2.8pp | -0.4%-9.0pp | 8.6%-4.2pp | 12.8% |
| Operating Margin | -21.6%-5.5pp | -16.0%+65.3pp | -81.3%-84.5pp | 3.1%+11.7pp | -8.5%+54.6pp | -63.1%-17.7pp | -45.4%-51.5pp | 6.1%+15.4pp | -9.4%-2.5pp | -6.9%-0.7pp | -6.2%+8.6pp | -14.7%-2.6pp | -12.1%-9.5pp | -2.6%-9.4pp | 6.8% |
| Net Margin | -11.1%+0.5pp | -11.6%+61.4pp | -73.0%-76.9pp | 3.9%+4.7pp | -0.8%+62.0pp | -62.8%-18.4pp | -44.4%-54.1pp | 9.7%+20.8pp | -11.1%-0.1pp | -11.0%-4.6pp | -6.4%+8.4pp | -14.8%+0.1pp | -14.9%-10.3pp | -4.6%-9.5pp | 4.9% |
| Return on Equity | -3.1%+3.0pp | -6.0%+18.8pp | -24.9%-26.2pp | 1.4%+1.5pp | -0.2%+45.5pp | -45.7%-2.4pp | -43.4%-51.0pp | 7.6%+18.6pp | -10.9%+0.6pp | -11.5%-4.8pp | -6.7%+5.6pp | -12.3%+2.6pp | -14.9%-10.0pp | -4.9%-14.3pp | 9.4% |
| Return on Assets | -2.8%+2.2pp | -5.0%+17.6pp | -22.6%-23.8pp | 1.2%+1.4pp | -0.2%+24.5pp | -24.7%+2.1pp | -26.8%-31.8pp | 5.0%+11.6pp | -6.6%+0.8pp | -7.4%-2.8pp | -4.6%+5.0pp | -9.6%+1.4pp | -11.0%-6.8pp | -4.2%-11.1pp | 7.0% |
| Current Ratio | 5.38+0.2x | 5.16-10.5x | 15.68+5.9x | 9.74-1.6x | 11.38+11.0x | 0.40+0.1x | 0.32-0.2x | 0.54+0.1x | 0.40-0.1x | 0.50-0.4x | 0.88-0.1x | 1.02+0.3x | 0.77-1.1x | 1.91+0.4x | 1.50 |
| Debt-to-Equity | 0.000.0x | 0.010.0x | 0.000.0x | 0.010.0x | 0.010.0x | 0.000.0x | 0.01-0.1x | 0.090.0x | 0.120.0x | 0.130.0x | 0.14+0.1x | 0.060.0x | 0.09+0.1x | 0.010.0x | 0.02 |
| FCF Margin | -95.5%-107.5pp | 12.0%+84.2pp | -72.2%-54.3pp | -17.9%+21.9pp | -39.8%-10.2pp | -29.6%-19.9pp | -9.7%+7.5pp | -17.2%-20.6pp | 3.4%+4.9pp | -1.4%+8.9pp | -10.3%+16.3pp | -26.6%-3.9pp | -22.7%+0.1pp | -22.8%-8.9pp | -13.9% |
Similar Companies
Where United States Antimony Ranks
Frequently Asked Questions
What is United States Antimony's annual revenue?
United States Antimony (UAMY) reported $39.3M in total revenue for fiscal year 2025. This represents a 162.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is United States Antimony's revenue growing?
United States Antimony (UAMY) revenue grew by 162.8% year-over-year, from $14.9M to $39.3M in fiscal year 2025.
Is United States Antimony profitable?
No, United States Antimony (UAMY) reported a net income of -$4.3M in fiscal year 2025, with a net profit margin of -11.1%.
What is United States Antimony's EBITDA?
United States Antimony (UAMY) had EBITDA of -$7.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does United States Antimony have?
As of fiscal year 2025, United States Antimony (UAMY) had $30.5M in cash and equivalents against $58K in long-term debt.
What is United States Antimony's gross margin?
United States Antimony (UAMY) had a gross margin of 25.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is United States Antimony's operating margin?
United States Antimony (UAMY) had an operating margin of -21.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is United States Antimony's net profit margin?
United States Antimony (UAMY) had a net profit margin of -11.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is United States Antimony's return on equity (ROE)?
United States Antimony (UAMY) has a return on equity of -3.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is United States Antimony's free cash flow?
United States Antimony (UAMY) recorded an outflow of $37.5M in free cash flow during fiscal year 2025. This represents a -2195.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is United States Antimony's operating cash flow?
United States Antimony (UAMY) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are United States Antimony's total assets?
United States Antimony (UAMY) had $153.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are United States Antimony's capital expenditures?
United States Antimony (UAMY) invested $27.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is United States Antimony's current ratio?
United States Antimony (UAMY) had a current ratio of 5.38 as of fiscal year 2025, which is generally considered healthy.
What is United States Antimony's debt-to-equity ratio?
United States Antimony (UAMY) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is United States Antimony's return on assets (ROA)?
United States Antimony (UAMY) had a return on assets of -2.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is United States Antimony's cash runway?
Based on fiscal year 2025 data, United States Antimony (UAMY) had $30.5M in cash against an annual operating cash burn of $9.7M. This gives an estimated cash runway of approximately 38 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is United States Antimony's Altman Z-Score?
United States Antimony (UAMY) has an Altman Z-Score of 38.02, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is United States Antimony's Piotroski F-Score?
United States Antimony (UAMY) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are United States Antimony's earnings high quality?
United States Antimony (UAMY) reported a net loss of $4.3M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is United States Antimony?
United States Antimony (UAMY) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.